Objective Several recent studies report that, after allogeneic hematopoietic cell transplantation (allo-HCT), eosinophilia is a favorable factor for transplant outcomes. However, whether the degree of eosinophilia influences transplant outcomes is yet to be established. Methods We studied 144 patients with hematological malignancy who received allo-HCT at our institution. The stem cell sources were bone marrow in 84 patients, peripheral blood stem cells in 32 patients, and cord blood in 28 patients. One hundred and twelve patients underwent myeloablative conditioning and 49 patients had high-risk disease. We performed semi-landmark analysis to examine the influence of eosinophilia.
Introduction
related to better outcomes in allogeneic hematopoietic cell transplantation (allo-HCT) (3) (4) (5) (6) . Better overall survival (OS) in patients with eosinophilia after allo-HCT was shown to be a result of the lower relapse rates (3), lower non-relapse mortality (NRM) (4) , and both lower relapse rates and NRM (5) . Recently, another study reported that eosinophilia still affected transplant outcomes in the subgroup of patients with acute graft-versus-host disease (GVHD) (6) , but no effect was seen in those patients that underwent cord blood transplantation (7) . Previous studies reported that activated tissue eosinophils were implicated in the pathogenesis of GVHD (8, 9) . Kim et al discussed the possibility that late eosinophilia might simply be a marker of Th2 cytokine activation and that activation of the Th2 pathway correlates with the recovery of humoral immunity, a component in the pathogenesis of chronic GVHD (5) . In addition, unlike mild chronic GVHD, severe chronic GVHD resulted in poor outcomes (10) . From this perspective, higher eosinophilia may enhance GVHD and thus worsen the prognosis. However, to our knowledge, no reports have addressed the question of the extent to which blood eosinophilia influences the outcome of allo-HCT. In this study, we therefore investigated how the existence and degree of eosinophilia after allo-HCT influenced transplant outcomes.
Materials and Methods

Patients
We retrospectively evaluated 182 consecutive patients with hematological malignancy who underwent allogeneic stem cell transplantation at our institute between January 2004 and April 2011. We excluded 18 patients who died before neutrophil engraftment, and 12 patients who underwent haplo-identical stem cell transplantation. We also excluded eight patients who died or experienced disease relapse or progression before the median onset of eosinophilia, to allow semi-landmark analysis. Ultimately, 144 patients were included in this analysis.
As it was difficult to obtain informed consent for this retrospective study, we made the context of this study known to the public by putting up a notice at our hospital and on our website in accordance with the ethical guidelines for epidemiological research compiled by both the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare in Japan. This retrospective study was approved by the Institutional Review Board of our institute.
Transplantation procedures
Myeloablative and reduced-intensity conditioning were used in 111 and 33 patients, respectively. We used the definition of conditioning intensity from previous reports (11, 12) . Myeloablative conditioning was used in 111 patients, with total body irradiation of 12 Grays in 42 patients and busulfan (Bu)-based conditioning in 62 patients.
In contrast, in the 33 patients who underwent reducedintensity conditioning, Bu-based conditioning was used in 20 patients, melphalan-based conditioning in 10 patients, and cyclophosphamide-based conditioning was used in two patients.
For acute GVHD prophylaxis, cyclosporine A was used alone in 10 patients, cyclosporine A and short-term methotrexate (sMTX) were used in 112 patients, cyclosporine A and mycophenolate mofetil (MMF) were used in five patients, tacrolimus was used alone in three patients, tacrolimus and sMTX were used in five patients, tacrolimus and MMF were used in eight patients, and no treatment was given to one patient. Antithymocyte globulin was used in just two patients. In 116 patients transplanted from either a related peripheral blood stem cell/ bone marrow donor or unrelated bone marrow donor, 93 pairs (sibling: 33; unrelated: 60) were matched for six of six HLA-A, B, and DRB1 alleles, and 23 pairs (related: 8; unrelated: 15) were matched for five of six of these alleles. In 28 patients transplanted with cord blood, seven pairs were serologically matched for five of six at HLA-A, B, and DR loci; 20 pairs were matched for four of six; and one pair was matched for three of six loci. Acute and chronic GVHD were evaluated based on established criteria (13, 14) . In general, grade II to IV acute GVHD was treated initially with prednisolone or methylprednisolone (1-2 mg/kg/day), except for grade II acute GVHD involving just the skin, following CBT.
Eosinophilia was defined as an absolute eosinophil count of!500×10 6 /L on microscopy of peripheral blood on at least two consecutive days after neutrophil engraftment, except for eosinophilia that occurred after relapse or progression of the original disease. We analyzed the influence on transplant outcome of not only the presence of eosinophilia, but also the degree of eosinophilia. The group with eosinophilia (63 patients) was stratified into two groups, the mild eosinophilia group (peripheral blood eosinophil count: 500-1,500×10 6 /L, 35 patients) and the hypereosinophilic group (more than 1,500×10 6 /L, 28 patients) based on the maximum eosinophil count after transplantation.
Statistics
To compare patient characteristics, the Chi-square and Wilcoxon tests were used for categorical and metric variables, respectively. To evaluate the effect of eosinophilia on OS, relapse, and non-relapse mortality (NRM), we employed "semi-landmark plots" (5) . In patients who developed eosinophilia, the day of onset after transplant was defined as the landmark day. On the other hand, in patients who did not develop eosinophilia, day 47 after transplant, which was the median onset day for eosinophilia, was defined as the landmark day. OS, relapse and NRM were calculated based on the interval from the landmark day. OS analyses were performed by the Kaplan-Meier method, and a log-rank test was employed to assess the difference between two groups. Cumulative incidences of NRM and relapse were analyzed under the assumption that they represented competing risks, and compared using Gray's test. For NRM, relapse was the competing event; for relapse, death without relapse was the competing event. The Cox proportional hazards model was used to test the statistical significance of several potential prognostic factors for OS, NRM, and relapse. Two factors, acute GVHD and systemic steroid therapy, were treated as time-dependent co-variates. We defined statistical significance as a P value of less than 0.05. Statistical analyses were performed using R version 2.11.1.
Results
Patient characteristics and eosinophilia
Patient characteristics are summarized in Table 1 . The median age at transplantation was 45.5 years (range: 16-69). These patients included 55 individuals with acute myeloid leukemia (AML); 31 with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) (ALL: 29, LBL: 2); four with acute leukemias of ambiguous lineage; eight with chronic myeloid leukemia (CML); 18 with myelodysplastic syndrome (MDS); 21 with aggressive lymphoma (adult T-cell leukemia/lymphoma: 13; diffuse large B-cell lymphoma: 3; peripheral T-cell lymphoma: 2; NK/T-cell lymphoma: 1; anaplastic large cell lymphoma: 2); six with indolent lymphoma (follicular lymphoma: 5 and mantle cell lymphoma: 1); and one with chronic, active Epstein-Barr virus infection (CAEBV). We considered the following patients to be at a standard disease risk: acute leukemia in the first or second complete remission (CR), CML in the first or second chronic phase, MDS in the absence of refractory anemia with excess blasts, indolent lymphoma (any status), aggressive lymphoma in complete remission, or CAEBV. All other patients were considered to be at high risk. Of 144 patients, 63 (44%) developed eosinophilia (Eo+). In the noneosinophilia (Eo-) group, ABO blood type matched to a significantly lesser degree than in the Eo+ group (43% and 63%, p=0.02). The remaining factors did not differ between the two groups. The use of systemic steroid therapy (prednisolone or methylprednisolone!0.5 mg/kg), and the incidence of acute and chronic GVHD were also not significantly different between the two groups. There was also no significant difference in the severity of chronic GVHD (no, limited and extensive chronic GVHD) between the mild and hyper-Eo+ sub-groups (p=0.67). The median time of onset of Eo+ was 47 days (range: 21-1,026) after allo-HCT, but eosinophilia tended to occur later after CBT (81.5 days) than after BMT and PBSCT (42 and 43.5 days, respectively) (p=0.05). The median maximum eosinophil count of Eo+ was 1,403×10 6 /L (range: 516-10,010×10 6 ), and there was no difference among those with BMT, PBSCT, or CBT (1,280, 1,210 and 1,740×10 6 , respectively, p=0.47). Of 144 patients, 51 patients (35%) died during the follow-up period and the median follow-up period of survivors was 1,072 days (range: 129-2,737) after the landmark day.
Relationship between eosinophilia and overall survival
The Eo+ group had a significantly better outcome (3 year OS: 66% in Eo+ group and 55% in Eo-group, p=0.04) (Fig. 1) . In addition, in the analysis that divided the Eo+ group into mild and hyper sub-groups, outcomes were similar (68% and 65%, p=0.92 
Correlation between eosinophilia and relapse or progression
As with OS, the Eo+ group had a significantly better outcome (three-year relapse or progression rate: 30% in the Eo+ group and 50% in the Eo-group, p=0.002) (Fig. 2) . Again, in the sub-analysis of the mild Eo+ and hyper-Eo+ sub-groups, both sub-groups had similar rates of relapse or progression (three-year relapse or progression rate: 31% in mild Eo+ group and 28% in hyper-Eo+ group, p=0.90). On univariate analysis, three factors were significant: female donor to male recipient [HR: 2. OS, overall survival; NRM, non-relapse mortality; HR, hazard ratio; CI, confidence interval; GVHD, graft versus host disease; RIC, reduced intensity conditioning; HLA, human leukocyte antigen; CMV, cytomegalovirus p=0.002) and Eo+: HR: 0.5 (95% CI: 0.3-0.9, p=0.01), respectively]. In the multivariate study of the mild and hyperEo+ sub-groups, both sub-groups had a tendency towards lower relapse than did the Eo-group [HR: 0.5 (95% CI: 0.2-1.01), p=0.05 and HR: 0.5 (95% CI: 0.2-1.1), p=0.07].
Influence of eosinophilia on NRM
Outcomes in the Eo+ group were similar to those in the Eo-group (three-year NRM: 10% in the Eo+ group and 14% in the Eo-group, p=0.22) (Fig. 3) . In the analysis that distinguished mild and hyper-Eo+ sub-groups, each outcome was also similar (three-year NRM: 10% in the mild Eo+ sub-group and 10% in the hyper-Eo+ sub-group, p=0.98). On univariate analysis, three factors, older age, grade II to IV acute GVHD and systemic steroid therapy, were associated with a significantly higher NRM [older age: HR: 2.1 (95% CI: 1.2-3.5), p=0.006; grade II to IV of acute GVHD: HR: 5.2 (95% CI: 1.2-23.1), p=0.03; and systemic steroid therapy: HR: 4.2 (95% CI: 1.2-14.9), p=0.03]. Eo+ showed a tendency to better NRM, but not significantly so [HR: 0.4 (95% CI: 0.1-1.2), p=0.11] ( Table 2) . On multivariate analysis, the same tendency was shown. In the multivariate study 
Discussion
In this study, we found that: 1) eosinophilia after allo-HCT was significantly associated with a lower incidence of relapse and tended to improve OS, and 2) differences in the degree of eosinophilia had no influence on the results. To our knowledge, four studies indicate better outcome after allo-HCT if eosinophilia is present (3) (4) (5) (6) . Two previous studies reported that eosinophilia after allo-SCT correlated with lower relapse rates (3, 5) , and three studies showed that eosinophilia after allo-SCT was associated with lower NRM (4) (5) (6) . On the other hand, one study found no relationship between eosinophilia and transplant outcome (7) . Of these five studies, just two reported median maximum eosinophil counts, which were 840.5×10 6 /L (3) and 1,180× 10 6 /L (7). However, no study has investigated the relationship between the grade of eosinophilia and transplant outcome, despite the concern that hypereosinophilia may cause tissue and organ damage, regardless of the underlying etiology (2) . In this study, therefore, we planned to address this specific point. We undertook the analysis, taking into consideration the potential for confounding between eosinophilia and the use of systemic steroids, especially with GVHD treatment, because eosinophilia is influenced by systemic steroid therapy. The median number of days after transplantation at which eosinophilia was detected was later than the median onset of acute GVHD [47 (range: 21-1,026) versus 19 (range: 3-133) days after transplantation, respectively], and in Eo+ patients with grade II to IV acute GVHD, many cases showed eosinophilia (33 of 37 patients) after the occurrence of acute GVHD. Therefore, if anything, we were concerned about a tendency to underestimate the incidence of eosinophilia, related to systemic steroid use for acute GVHD, grades II to IV. However, there was no difference in the incidence of eosinophilia at any grade of acute GVHD [none or grade I: 26 of 57 patients (46%); grades II to IV: 37 of 87 patients (43%)]. We speculate that systemic steroid use did not necessarily decrease eosinophilia, although it might account for the observed delay. On multivariate analysis, we included systemic steroid use in order to analyze its influence on eosinophilia, so as to compensate for potential confounding effects. As a result, we believe we were able to minimize the influence of confounding effects in this study.
One previous study reported that there was no correlation between eosinophilia and transplant outcome in CBT (7) . However, in the present study, we also found favorable outcomes in CBT, as with BMT and PBSCT (data not shown); we therefore included cases with CBT in this analysis. We cannot easily explain why our results differ, but outcomes may depend on differences in transplant conditions, such as patients' ages, disease status, conditioning regimens, and the timing of systemic steroid therapy.
Eosinophilia after allo-SCT may reflect the recovery of Th2/Tc2 cells. Th2 cytokines including IL-4, IL-5 and IL-10 are produced by CD4 Th2/ CD8 Tc2 cells and appear to be important in the process of chronic GVHD (15) , which was reported to be related to graft-versus-tumor (GVT) effect (16) . Therefore, eosinophilia after allo-HCT may lead to fewer relapses and improved OS via the activation of the GVT effect. The present study also showed that eosinophilia after allo-HCT was associated with a trend towards lower NRM, although not significantly so. Th2 pathway activation possibly causes a decline in Th1 pathway activity, which plays an important role in the deleterious effects of acute GVHD, and thereby correlates with lower NRM (3) (4) (5) .
Regarding the degree of eosinophilia, our results showed no difference between the mild and hyper-eosinophilia subgroups as regards both transplant outcome and severity of acute and chronic GVHD. In their review, Roufosse and Weller discuss that we should watch and wait if hypereosinophilia is asymptomatic, and that we must look for organ involvement at regular intervals and thereby determine the clinical urgency for use of an eosinophil-lowering agent (2) . Another study determined that the extent of tissue eosinophilic infiltration varies and usually does not correlate with peripheral blood eosinophilia (17) . Moreover, several studies reported an inhibitory effect of calcineurin inhibitors on eosinophilic infiltration (18) (19) (20) . We speculate that where there is blood eosinophilia after allo-HCT, tissue infiltration may not correlate well with higher blood eosinophilia because of the use of immunosuppressive drugs. Further consideration of organ infiltration is needed to make a clinical decision as to whether we should use steroids to treat marked and persistent eosinophilia after transplantation.
This study has the following limitations: 1) it is a retrospective study from a single institution; 2) the patients encompass a variety of diseases, disease statuses, donor sources, conditioning regimens and approaches to GVHD prophylaxis.
In conclusion, eosinophilia after allo-HCT may be associated with better OS and a lower relapse rate, regardless of the extent of eosinophilia. Higher degrees of eosinophilia may not have an adverse influence on transplant outcome. Further studies are necessary to clarify the relationship between the degree of blood eosinophilia and organ infiltration after allo-HCT, with investigation of the pathophysiological processes involved.
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